
Electra Therapeutics, Inc.
ETRAPricedElectra Therapeutics, Inc. · Nasdaq Global Select Market · Research source · 424B4 · 2026-09-18 · Latest filing · 10-Q · 2026-11-12 SEC ↗
IPO research
Electra Therapeutics’ filed 424B4 prospectus describes a $15.00-per-share IPO of 23,333,334 common shares, with expected delivery on or about September 21, 2026, subject to completion conditions.
Full source-backed summary
As of the September 17, 2026 prospectus and September 18, 2026 filing, Electra Therapeutics is offering a priced IPO of common stock to fund late-stage clinical development, but remains pre-revenue, loss-making, dependent on clinical and regulatory execution, and subject to substantial financing and manufacturing risks. The filing does not establish that trading or closing has occurred.
Electra Therapeutics’ filed 424B4 prospectus describes a $15.00-per-share IPO of 23,333,334 common shares, with expected delivery on or about September 21, 2026, subject to completion conditions.
- Business and development direction
Electra Therapeutics, Inc.
Current business Future development
Key risks
Risk 1
Positive early clinical results may not predict registrational or later-stage outcomes; enrollment and regulatory approval remain uncertain.
Risk 2
The company states it has no approved products, no revenue and expects significant future losses; additional capital may be required even after the offering.
Risk 3
The CMO facility received FDA Form 483 observations and OAI classification; remediation and shutdown timing are uncertain and could delay a BLA.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio · calculated | Shares |
|---|---|---|---|---|
| 1 | Jefferies LLC | 35.50% | 8,283,334 shares | |
| 2 | TD Securities (USA) LLC | 28.00% | 6,533,334 shares | |
| 3 | Evercore Group L.L.C. | 20.50% | 4,783,333 shares | |
| 4 | Cantor Fitzgerald & Co. | 16.00% | 3,733,333 shares |
Ratio = institution commitment ÷ complete source-table total (23,333,334 shares) × 100.
Underwriting terms
| Measure | Reported value | Unit |
|---|---|---|
| Underwriting discount per share | $1.05 | $ / share |
| Total underwriting discount | $24,500,001 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 4; source 3299:5994; SHA256 2496f3e15c8cf9394209f9004a123c30d5b63b8546860d5d8219c1e89088eae5 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 4; source 3299:5994; SHA256 2496f3e15c8cf9394209f9004a123c30d5b63b8546860d5d8219c1e89088eae5 ↗IPO CAPITAL QUALITY
Basis and evidence
424B4 · 2026-09-18
Electra Therapeutics’ filed 424B4 prospectus describes a $15.00-per-share IPO of 23,333,334 common shares, with expected delivery on or about September 21, 2026, subject to completion conditions.
Offering structure
| Measure | Reported value | Unit |
|---|---|---|
| Shares offered | 23,333,334 | Shares |
| Offering price | $15 | $ / share |
| Gross offering amount | $350,000,010 | $ |
Source and calculation
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
SEC table 33 row 1; source 79167:79528; SHA256 649924c708c48b3901933b97d3774de549b7c2ca389f6ff3f7f939e58f53ae23 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 3; source 3299:5994; SHA256 2496f3e15c8cf9394209f9004a123c30d5b63b8546860d5d8219c1e89088eae5 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 3; source 3299:5994; SHA256 2496f3e15c8cf9394209f9004a123c30d5b63b8546860d5d8219c1e89088eae5 ↗Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Use of proceeds | Source-linked structured inputs are not yet available. Open filing ↗ |
Dilution and valuation
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Base post-offer valuation | ≈ 62.767M | ≈ $941.5043M | |
| Post-offer shares — base/no option | 62,766,955 | — | |
| Post-offer shares — full option | 66,266,955 | — | |
| Capitalization shares — actual | 29,329 | — | |
| Capitalization shares — pro forma | 39,433,621 | — | |
| Capitalization shares — pro forma as adjusted | 62,766,955 | — | |
| Shares offered | 23,333,334 | — | |
| Offering price | — | $15 | |
| Gross offering amount | — | $350,000,010 |
Basis and evidence ↗
Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: actual; Common stock, $0.0001 par value; 71,000,000 shares authorized, 29,329 shares issued and outstanding, actual; 900,000,000 shares authorized, pro forma and pro forma as adjusted; 39,433,621 shares issued and outstanding, pro forma; 62,766,955 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma; Common stock, $0.0001 par value; 71,000,000 shares authorized, 29,329 shares issued and outstanding, actual; 900,000,000 shares authorized, pro forma and pro forma as adjusted; 39,433,621 shares issued and outstanding, pro forma; 62,766,955 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma as adjusted; Common stock, $0.0001 par value; 71,000,000 shares authorized, 29,329 shares issued and outstanding, actual; 900,000,000 shares authorized, pro forma and pro forma as adjusted; 39,433,621 shares issued and outstanding, pro forma; 62,766,955 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Offering price: $15
Exact input · Post-offer shares — base/no option: 62,766,955
Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — full option: 66,266,955
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 62,766,955 shares (or 66,266,955 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — base/no option: 62,766,955
Exact input · Offering price: $15
Share-count comparison
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source ↗IPO valuation scenario simulator
Offering completion · $15 × ≈ 62.767M shares · Final
Source and calculation ↗
Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.
Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.
Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.
The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
$15 × 62,766,955 = $941,504,325 [summary-table-35-base-1-price, summary-table-35-base-1-post]
Exact calculation · Derived whole-issuer equity value: $941,504,325
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
- As of
- 2026-09-18
Relationship filters
Select for details · Electra Therapeutics, Inc.
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| our executive officers, directors and stockholders whoOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: owned; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group); source scope: of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately; not an additive ownership partition |
| our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliatesOwnership as disclosed | — | approximately 33.1%Beneficial | — | Source statement; approximately ; source predicate: will, in the aggregate, hold; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group); source scope: of our outstanding common stock (based on the number of shares of common stock outstanding as of June 30, 2026 and after the conversion of all outstanding redeemable convertible preferred stock immed; not an additive ownership partition |
| WestlakeOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: holds; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| Electra Therapeutics LLCBeneficial shares | 15,065,741 | — | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER |
| Entities affiliated with OrbiMedBeneficial shares | 3,549,527 | — | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER |
| Entities affiliated with OrbiMedBeneficial shares | 5,551,837 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| Entities affiliated with Westlake BioPartners Fund I, L.P.Beneficial shares | 2,820,403 | — | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER |
| Entities affiliated with Westlake BioPartners Fund I, L.P.Beneficial shares | 6,347,539 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| Redmile Biopharma Investments II, L.P.Beneficial shares | 2,811,887 | — | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER |
| Redmile Biopharma Investments II, L.P.Beneficial shares | 4,796,215 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| Aventis Inc.Beneficial shares | 2,461,948 | — | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER |
| Aventis Inc.Beneficial shares | 2,461,948 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| LSP 7 Coöperatief U.A.Beneficial shares | 2,461,948 | — | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER |
| LSP 7 Coöperatief U.A.Beneficial shares | 2,461,948 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| Entities affiliated with New Leaf VenturesBeneficial shares | 1,722,233 | — | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER |
| Electra Therapeutics LLCBeneficial ownership | — | 38.2%Beneficial | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE |
| Entities affiliated with OrbiMedBeneficial ownership | — | 9%Beneficial | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE |
| Entities affiliated with OrbiMedBeneficial ownership | — | 8.8%Beneficial | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE |
| Entities affiliated with Westlake BioPartners Fund I, L.P.Beneficial ownership | — | 7.1%Beneficial | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE |
| Entities affiliated with Westlake BioPartners Fund I, L.P.Beneficial ownership | — | 10.1%Beneficial | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE |
| Redmile Biopharma Investments II, L.P.Beneficial ownership | — | 7.1%Beneficial | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE |
| Redmile Biopharma Investments II, L.P.Beneficial ownership | — | 7.6%Beneficial | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE |
| Aventis Inc.Beneficial ownership | — | 6.2%Beneficial | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE |
| Aventis Inc.Beneficial ownership | — | 3.9%Beneficial | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE |
| LSP 7 Coöperatief U.A.Beneficial ownership | — | 6.2%Beneficial | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE |
| LSP 7 Coöperatief U.A.Beneficial ownership | — | 3.9%Beneficial | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE |
| Entities affiliated with New Leaf VenturesBeneficial ownership | — | 4.4%Beneficial | — | SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE |
| Entities affiliated with New Leaf VenturesBeneficial shares | 3,248,304 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| Quehuong (Kathy) Dong, Pharm.D., M.B.A.Beneficial shares | 1,399,175 | — | — | SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER |
| Quehuong (Kathy) Dong, Pharm.D., M.B.A.Beneficial shares | 1,854,659 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| Gary S. Koe, Ph.D.Beneficial shares | 380,837 | — | — | SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER |
| Gary S. Koe, Ph.D.Beneficial shares | 444,493 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| Kim-Hien Dao, D.O., Ph.D.Beneficial shares | 547,202 | — | — | SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER |
| Kim-Hien Dao, D.O., Ph.D.Beneficial shares | 547,202 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| Matthew Fust, M.B.A.Beneficial shares | 136,800 | — | — | SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER |
| Matthew Fust, M.B.A.Beneficial shares | 136,800 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| Carl L. Gordon, Ph.D., C.F.A.Beneficial shares | 3,549,527 | — | — | SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER |
| Carl L. Gordon, Ph.D., C.F.A.Beneficial shares | 5,551,837 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| Beth Seidenberg, M.D.Beneficial shares | 2,820,403 | — | — | SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER |
| Entities affiliated with New Leaf VenturesBeneficial ownership | — | 5.2%Beneficial | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE |
| Quehuong (Kathy) Dong, Pharm.D., M.B.A.Beneficial ownership | — | 3.4%Beneficial | — | SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE |
| Quehuong (Kathy) Dong, Pharm.D., M.B.A.Beneficial ownership | — | 3%Beneficial | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE |
| Kim-Hien Dao, D.O., Ph.D.Beneficial ownership | — | 1.4%Beneficial | — | SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE |
| Carl L. Gordon, Ph.D., C.F.A.Beneficial ownership | — | 9%Beneficial | — | SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE |
| Carl L. Gordon, Ph.D., C.F.A.Beneficial ownership | — | 8.8%Beneficial | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE |
| Beth Seidenberg, M.D.Beneficial ownership | — | 7.1%Beneficial | — | SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE |
| Beth Seidenberg, M.D.Beneficial ownership | — | 10.1%Beneficial | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE |
| Nancy Stagliano, Ph.D.Beneficial ownership | — | 1%Beneficial | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE |
| All directors and executive officers as a group (10 persons)Beneficial ownership | — | 23.2%Beneficial | — | SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE |
| All directors and executive officers as a group (10 persons)Beneficial ownership | — | 24.4%Beneficial | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE |
| Beth Seidenberg, M.D.Beneficial shares | 6,347,539 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| Nancy Stagliano, Ph.D.Beneficial shares | 383,352 | — | — | SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER |
| Nancy Stagliano, Ph.D.Beneficial shares | 638,987 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| All directors and executive officers as a group (10 persons)Beneficial shares | 9,994,008 | — | — | SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER |
| All directors and executive officers as a group (10 persons)Beneficial shares | 16,383,733 | — | — | SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER |
| Executive officers, directors, pre-offering >5%stockholders and their respective affiliatesOwnership as disclosed | — | approximately 33.1%Beneficial | — | Literal complete collective group; Immediately after offering; Approximately33.1%; June30,2026basis after preferred-stock conversion; no group purchases. Percentage applies to the source complete group, not any individual or truncated subgroup; full original conditions retained. |
| common stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained |
Source and calculation ↗
Source statement; >; source predicate: owned; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group); source scope: of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately; not an additive ownership partition
Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately 33.1% of our outstanding common stock (based on the number of shares of common stock outstanding as of June 30, 2026 and after the conversion of all outstanding redeemable convertible preferred stock immediately prior to the closing of this offering, assuming no purchase of shares in this offering by any of this group). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily of those of other stockholders, including seeking a premium value for their common stock. Any of these actions could adversely affect the market price of our common stock.
Source statement; approximately ; source predicate: will, in the aggregate, hold; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group); source scope: of our outstanding common stock (based on the number of shares of common stock outstanding as of June 30, 2026 and after the conversion of all outstanding redeemable convertible preferred stock immed; not an additive ownership partition
Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately 33.1% of our outstanding common stock (based on the number of shares of common stock outstanding as of June 30, 2026 and after the conversion of all outstanding redeemable convertible preferred stock immediately prior to the closing of this offering, assuming no purchase of shares in this offering by any of this group). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily of those of other stockholders, including seeking a premium value for their common stock. Any of these actions could adversely affect the market price of our common stock.
Source statement; >; source predicate: holds; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Westlake holds more than 5% of our outstanding capital stock. Dr. Seidenberg, a member of our board of directors, is the sole managing director of Westlake BioPartners GP II, LLC, the general partner of Westlake. Dr. Seidenberg resigned from our board of directors as of immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: Electra Therapeutics LLC (1)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: Entities affiliated with OrbiMed (2)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Entities affiliated with OrbiMed (2)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: Entities affiliated with Westlake BioPartners Fund I, L.P. (3)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Entities affiliated with Westlake BioPartners Fund I, L.P. (3)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: Redmile Biopharma Investments II, L.P. (4)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Redmile Biopharma Investments II, L.P. (4)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: Aventis Inc. (5)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Aventis Inc. (5)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: LSP 7 Coöperatief U.A. (6)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: LSP 7 Coöperatief U.A. (6)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; NUMBER; source holder: Entities affiliated with New Leaf Ventures (7)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: Electra Therapeutics LLC (1)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: Entities affiliated with OrbiMed (2)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Entities affiliated with OrbiMed (2)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: Entities affiliated with Westlake BioPartners Fund I, L.P. (3)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Entities affiliated with Westlake BioPartners Fund I, L.P. (3)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: Redmile Biopharma Investments II, L.P. (4)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Redmile Biopharma Investments II, L.P. (4)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: Aventis Inc. (5)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Aventis Inc. (5)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: LSP 7 Coöperatief U.A. (6)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: LSP 7 Coöperatief U.A. (6)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TO OFFERING; PERCENTAGE; source holder: Entities affiliated with New Leaf Ventures (7)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Entities affiliated with New Leaf Ventures (7)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Quehuong (Kathy) Dong, Pharm.D., M.B.A. (8)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Quehuong (Kathy) Dong, Pharm.D., M.B.A. (8)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Gary S. Koe, Ph.D. (9)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Gary S. Koe, Ph.D. (9)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Kim-Hien Dao, D.O., Ph.D. (10)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Kim-Hien Dao, D.O., Ph.D. (10)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Matthew Fust, M.B.A. (11)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Matthew Fust, M.B.A. (11)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Carl L. Gordon, Ph.D., C.F.A. (13)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Carl L. Gordon, Ph.D., C.F.A. (13)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Beth Seidenberg, M.D. (14)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Entities affiliated with New Leaf Ventures (7)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; source holder: Quehuong (Kathy) Dong, Pharm.D., M.B.A. (8)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Quehuong (Kathy) Dong, Pharm.D., M.B.A. (8)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; source holder: Kim-Hien Dao, D.O., Ph.D. (10)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; source holder: Carl L. Gordon, Ph.D., C.F.A. (13)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Carl L. Gordon, Ph.D., C.F.A. (13)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; source holder: Beth Seidenberg, M.D. (14)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Beth Seidenberg, M.D. (14)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: Nancy Stagliano, Ph.D. (15)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; PERCENTAGE; source holder: All directors and executive officers as a group (10 persons) (16)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; PERCENTAGE; source holder: All directors and executive officers as a group (10 persons) (16)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Beth Seidenberg, M.D. (14)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: Nancy Stagliano, Ph.D. (15)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: Nancy Stagliano, Ph.D. (15)
Exact source ownership column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED PRIOR TOOFFERING; NUMBER; source holder: All directors and executive officers as a group (10 persons) (16)
Exact source ownership column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; holders may overlap; not an additive partition
Raw source column: SHARES BENEFICIALLYOWNED AFTER OFFERING; NUMBER; source holder: All directors and executive officers as a group (10 persons) (16)
Literal complete collective group; Immediately after offering; Approximately33.1%; June30,2026basis after preferred-stock conversion; no group purchases. Percentage applies to the source complete group, not any individual or truncated subgroup; full original conditions retained.
Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately 33.1% of our outstanding common stock (based on the number of shares of common stock outstanding as of June 30, 2026 and after the conversion of all outstanding redeemable convertible preferred stock immediately prior to the closing of this offering, assuming no purchase of shares in this offering by any of this group). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily of those of other stockholders, including seeking a premium value for their common stock. Any of these actions could adversely affect the market price of our common stock.
Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained
Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of stockholders, except as otherwise expressly provided in our amended and restated certificate of incorporation or required by applicable law. There are no cumulative voting rights. Source context: Upon the filing of our amended and restated certificate of incorporation and the closing of this offering, our authorized capital stock will consist of 900,000,000 shares of our common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. All of our authorized preferred stock upon the closing of this offering will be undesignated. The following is a summary of the rights of our common and preferred stockholders and some of the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective upon the closing of this offering, and of the DGCL. This summary is not complete. For more detailed information, please see our amended and restated certificate of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the DGCL.
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
Share supply
Source lock-up conditions
Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| Each of our officers, directors and substantially all of our stockholdersAfter date of this prospectus · Source conditions apply | 180 days |
| We, our directors, executive officers, and the holders of substantially all of our equity securities,After date of this prospectus · Source conditions apply | 180 days |
Source and calculation
Based on 39,433,621 shares of our capital stock outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, upon completion of this offering, we will have a total of 62,766,955 shares of common stock outstanding. Of these shares, only the 23,333,334 shares of common stock sold in this offering, or 26,833,334 shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on 39,433,621 shares outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, approximately all 39,433,621 shares of common stock will be eligible for sale in the public market, of which approximately 14,729,214 shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended (Securities Act). See the section titled “Executive and Director Compensation—Narrative to Summary Compensation Table—Equity-based Incentive Awards” for additional information about Electra LLC. Prior to the closing of this offering, Electra LLC distributed shares of our Series A redeemable convertible preferred stock to the unit holders of Electra LLC, which includes certain of our officers, directors and their affiliated entities.
SEC lock-up paragraph; source 621547:624047; SHA256 2225dfcabaa3ef83fbd5e0984db6b2fe7330ff95b447eed817fd9ab20584234a ↗We, our directors, executive officers, and the holders of substantially all of our equity securities, have agreed with the underwriters that for a period of 180 days after the date of this prospectus, subject to specified exceptions as detailed further in the section titled “Underwriting,” we will not, except with the prior written consent of Jefferies LLC, TD Securities (USA) LLC and Evercore Group L.L.C., and they will not, except with the prior written consent of Jefferies LLC and TD Securities (USA) LLC, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to sell or otherwise dispose of, or transfer any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, request or demand that we file a registration statement related to our common stock, or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Substantially all of our optionholders are subject to a market stand-off agreement with us, which imposes similar restrictions.
SEC lock-up paragraph; source 1663905:1665273; SHA256 316c0e61b8bb2bc34db2575f643d1d9dd6ab459888dd6c4d84d3a6417567d000 ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
date of this prospectus
- Each of our officers, directors and substantially all of our stockholdersBased on 39,433,621 shares of our capital stock outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, upon completion of this offering, we will have a total of 62,766,955 shares of common stock outstanding. Of these shares, only the 23,333,334 shares of common stock sold in this offering, or 26,833,334 shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on 39,433,621 shares outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, approximately all 39,433,621 shares of common stock will be eligible for sale in the public market, of which approximately 14,729,214 shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended (Securities Act). See the section titled “Executive and Director Compensation—Narrative to Summary Compensation Table—Equity-based Incentive Awards” for additional information about Electra LLC. Prior to the closing of this offering, Electra LLC distributed shares of our Series A redeemable convertible preferred stock to the unit holders of Electra LLC, which includes certain of our officers, directors and their affiliated entities.
- We, our directors, executive officers, and the holders of substantially all of our equity securities,We, our directors, executive officers, and the holders of substantially all of our equity securities, have agreed with the underwriters that for a period of 180 days after the date of this prospectus, subject to specified exceptions as detailed further in the section titled “Underwriting,” we will not, except with the prior written consent of Jefferies LLC, TD Securities (USA) LLC and Evercore Group L.L.C., and they will not, except with the prior written consent of Jefferies LLC and TD Securities (USA) LLC, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to sell or otherwise dispose of, or transfer any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, request or demand that we file a registration statement related to our common stock, or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Substantially all of our optionholders are subject to a market stand-off agreement with us, which imposes similar restrictions.
| Holder / event | Term / date | Conditions |
|---|---|---|
| Each of our officers, directors and substantially all of our stockholders | 180 days | Based on 39,433,621 shares of our capital stock outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, upon completion of this offering, we will have a total of 62,766,955 shares of common stock outstanding. Of these shares, only the 23,333,334 shares of common stock sold in this offering, or 26,833,334 shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on 39,433,621 shares outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, approximately all 39,433,621 shares of common stock will be eligible for sale in the public market, of which approximately 14,729,214 shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended (Securities Act). See the section titled “Executive and Director Compensation—Narrative to Summary Compensation Table—Equity-based Incentive Awards” for additional information about Electra LLC. Prior to the closing of this offering, Electra LLC distributed shares of our Series A redeemable convertible preferred stock to the unit holders of Electra LLC, which includes certain of our officers, directors and their affiliated entities. |
| We, our directors, executive officers, and the holders of substantially all of our equity securities, | 180 days | We, our directors, executive officers, and the holders of substantially all of our equity securities, have agreed with the underwriters that for a period of 180 days after the date of this prospectus, subject to specified exceptions as detailed further in the section titled “Underwriting,” we will not, except with the prior written consent of Jefferies LLC, TD Securities (USA) LLC and Evercore Group L.L.C., and they will not, except with the prior written consent of Jefferies LLC and TD Securities (USA) LLC, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to sell or otherwise dispose of, or transfer any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, request or demand that we file a registration statement related to our common stock, or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Substantially all of our optionholders are subject to a market stand-off agreement with us, which imposes similar restrictions. |
Basis and evidence
Based on 39,433,621 shares of our capital stock outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, upon completion of this offering, we will have a total of 62,766,955 shares of common stock outstanding. Of these shares, only the 23,333,334 shares of common stock sold in this offering, or 26,833,334 shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on 39,433,621 shares outstanding as of June 30, 2026, assuming the automatic conversion of our outstanding redeemable convertible preferred stock as of June 30, 2026, approximately all 39,433,621 shares of common stock will be eligible for sale in the public market, of which approximately 14,729,214 shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended (Securities Act). See the section titled “Executive and Director Compensation—Narrative to Summary Compensation Table—Equity-based Incentive Awards” for additional information about Electra LLC. Prior to the closing of this offering, Electra LLC distributed shares of our Series A redeemable convertible preferred stock to the unit holders of Electra LLC, which includes certain of our officers, directors and their affiliated entities.
SEC lock-up paragraph; source 621547:624047; SHA256 2225dfcabaa3ef83fbd5e0984db6b2fe7330ff95b447eed817fd9ab20584234a ↗We, our directors, executive officers, and the holders of substantially all of our equity securities, have agreed with the underwriters that for a period of 180 days after the date of this prospectus, subject to specified exceptions as detailed further in the section titled “Underwriting,” we will not, except with the prior written consent of Jefferies LLC, TD Securities (USA) LLC and Evercore Group L.L.C., and they will not, except with the prior written consent of Jefferies LLC and TD Securities (USA) LLC, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to sell or otherwise dispose of, or transfer any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, request or demand that we file a registration statement related to our common stock, or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Substantially all of our optionholders are subject to a market stand-off agreement with us, which imposes similar restrictions.
SEC lock-up paragraph; source 1663905:1665273; SHA256 316c0e61b8bb2bc34db2575f643d1d9dd6ab459888dd6c4d84d3a6417567d000 ↗Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Net income / (loss)
$ · Annual values as reportedOperating cash flow
$ · Annual values as reported| Calculation | FY2024 | FY2025 |
|---|---|---|
| Net income / (loss) | ($24,786,000) | ($61,975,000) |
| Operating cash flow | ($26,003,000) | ($60,484,000) |
| Calculation | Reported value |
|---|---|
| Cash and cash equivalents2025-12-31 | $33,008,000 |
| Cash and cash equivalents2024-12-31 | $14,787,000 |
| Current assets2025-12-31 | $95,486,000 |
| Current assets2024-12-31 | $19,420,000 |
| Total assets2025-12-31 | $99,368,000 |
| Total assets2024-12-31 | $19,420,000 |
| Current liabilities2025-12-31 | $9,726,000 |
| Current liabilities2024-12-31 | $4,195,000 |
| Total liabilities2025-12-31 | $11,208,000 |
| Total liabilities2024-12-31 | $4,195,000 |
| Total equity / (deficit)2025-12-31 | ($163,442,000) |
| Total equity / (deficit)2024-12-31 | ($103,261,000) |
| General and administrative expensesFY2025 | $10,390,000 |
| General and administrative expensesFY2024 | $5,241,000 |
| Cash and cash equivalents2026-06-30 · Unaudited | $66,507,000 |
| Cash and cash equivalents2025-12-31 · Unaudited | $33,008,000 |
| Current assets2026-06-30 · Unaudited | $100,361,000 |
| Current assets2025-12-31 · Unaudited | $95,486,000 |
| Total assets2026-06-30 · Unaudited | $106,498,000 |
| Total assets2025-12-31 · Unaudited | $99,368,000 |
| Current liabilities2026-06-30 · Unaudited | $13,626,000 |
| Current liabilities2025-12-31 · Unaudited | $9,726,000 |
| Total liabilities2026-06-30 · Unaudited | $14,782,000 |
| Total liabilities2025-12-31 · Unaudited | $11,208,000 |
| Total equity / (deficit)2026-06-30 · Unaudited | ($219,455,000) |
| Total equity / (deficit)2025-12-31 · Unaudited | ($163,442,000) |
Basis and evidence
Financial quality and runway
Financial quality and runway
The latest supplied period is the six months ended June 30, 2026, with balance-sheet data as of that date. The excerpts show R&D expense of $41.637 million and G&A expense of $8.593 million for the six months, cash, cash equivalents and marketable securities of $97.725 million, and accumulated deficit of $221.890 million. Full revenue, net-loss, debt and cash-flow totals are unavailable in the excerpts. A 2025 going-concern explanatory paragraph is disclosed.
EvidenceFinancial review 1Six-month 2026 R&D expense was $41.637 million versus $18.792 million in six-month 2025; G&A was $8.593 million versus $5.921 million.
+
Six-month 2026 R&D expense was $41.637 million versus $18.792 million in six-month 2025; G&A was $8.593 million versus $5.921 million.
EvidenceFinancial review 2June 30, 2026 cash, cash equivalents and marketable securities were $97.725 million before the offering and $417.575 million on a pro forma as-adjusted basis.
+
June 30, 2026 cash, cash equivalents and marketable securities were $97.725 million before the offering and $417.575 million on a pro forma as-adjusted basis.
EvidenceFinancial review 3The independent auditor’s 2025 report included a going-concern explanatory paragraph, creating a material financing dependency.
+
The independent auditor’s 2025 report included a going-concern explanatory paragraph, creating a material financing dependency.
MATERIAL CHANGES
The latest material signals and their investor impact are shown below.
Why it mattersBase shares increased from 21,666,667 to 23,333,334 and the expected price range was replaced by a $15.00 fixed price; the underwriter option increased from 3,250,000 to 3,500,000 shares.
Evidence · THE OFFERINGWhy it mattersPost-offering shares increased from 61,100,288 to 62,766,955; estimated net proceeds increased from approximately $296.6 million to $319.9 million, excluding full exercise.
Evidence · THE OFFERINGWhy it mattersReported dilution per new share decreased from $8.68 to $8.47, based on the final terms.
Evidence · Dilution424B40001193125-26-395670 ↗
Loading filing history…
Positive early clinical results may not predict registrational or later-stage outcomes; enrollment and regulatory approval remain uncertain.
- Evidence
- Summary of Risk Factors ↗
The company states it has no approved products, no revenue and expects significant future losses; additional capital may be required even after the offering.
- Evidence
- Summary of Risk Factors ↗